Imatinib mesylate inhibits CD4+CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors

Nicolas Larmonier, Nona Janikashvili, Collin James Lacasse, Claire Billerey Larmonier, Jessica Cantrell, Elaine Situ, Tamara Lundeen, Bernard Bonnotte, Emmanuel Katsanis

Research output: Contribution to journal › Article › peer-review

150 Scopus citations

Fingerprint

Dive into the research topics of 'Imatinib mesylate inhibits CD4+CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors'. Together they form a unique fingerprint.

Immunology and Microbiology

Keyphrases

Biochemistry, Genetics and Molecular Biology

Pharmacology, Toxicology and Pharmaceutical Science